Skip to main content
OpenTrials
Completed

NCT Number: NCT04191525

Phase II Clinical Trial to Evaluate the Efficacy and Safety of the Treatment With BPL-1 in Adult Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus type 2 (T2DM) is a chronic and progressive disease, characterized mainly by hyperglycemia. Metabolic imbalance causes an increased risk of microvascular and macrovascular complications associated with the increased prevalence of cardiovascular disease (CVD) in diabetics.

Although genetic predisposition determines individual susceptibility to T2DM, external factors such as an unhealthy diet and a sedentary lifestyle condition the onset of the disease.

Since T2DM is a multifactorial disease, many authors have studied the possible role of the microbiota and its alterations in the pathophysiology of the disease. There is evidence that in T2DM there are alterations in the proportion of Firmicutes, Bacteroidetes and Proteobacteria, and a smaller amount of bifidobacteria with anti-inflammatory properties.

Probiotics are living microorganisms present in food that, if consumed in sufficient quantities, can improve health. In general, probiotics protect the patient through immunomodulation, protecting him from infections, increasing the activation of mononuclear cells and lymphocytes.

The investigational product is a supplement to the probiotic Bifidobacterium animalis subsp. lactis (BPL-1) CECT 8145. There are numerous studies carried out on different strains of GLP-1 that demonstrate its safety. Many of them are commonly used in the food industry, not only because of their proven safety, but also because of their viability until consumption.

This clinical trial is proposed as an interdisciplinary study that can contribute to the characterization of the efficacy of treatment with probiotics in patients with T2DM of different stages of evolution, without and with hepatic involvement.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Diabetes Mellitus, Type 2 Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hospital Universitario de La princesa

Madrid, 28006, Spain

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male and female patients between the ages of 18-75 (inclusive)
  • BMI ≥ 27
  • Glycated hemoglobin > 5,6 and/or fasting glucose > 100 mg/dl and/or being on active treatment with at least one antidiabetic medication
  • Subjects must be able to provide written informed consent
  • Females of childbearing potential must have a previous negative pregnancy test and must agree to use adequate contraception during their participation in the study

Exclusion criteria

  • Crohn's disease, liver cirrhosis, human immunodeficiency virus (HIV) or any other active systemic bacterial, viral or fungal infections
  • BMI > 42
  • Severe hypoglycemias within 3 months prior to the start date of the study
  • Abnormal glycated hemoglobin measurements (over 8%) prior to the start date of the study
  • Prescription of a new antidiabetic medication in the last 6 months
  • Celiac disease or any other food intolerances
  • Use of antibiotics, probiotics and/or prebiotics within 2 weeks prior to the start date of the study
  • Chronic liver disease with a C Child-Plug score, chronic kidney disease with creatinine clearance < 50 ml/min as well as any other clinically significant conditions including pulmonary, neurological and cardiovascular diseases according to the investigators medical opinion
  • Patients with history or presence of malignancy who have been treated with systemic antineoplastic therapy within 6 months prior to the start date of the study
  • Pregnancy and breastfeeding
  • Not being able to provide written informed consent to participate in the study or to cooperate and comply with the study procedures for any other reason

Treatment and study plan

BPL-1 Probiotic capsules

Dietary Supplement

BPL-1 Probiotic 1 capsule/day

Placebo

Dietary Supplement

Placebo masked with the same presentation as the experimental product 1 capsule/day

Primary outcomes

  1. Fasting glucose

    Time frame: 12 weeks

    Fasting glucose

  2. Glycated haemoglobin

    Time frame: 12 weeks

    Glycated haemoglobin

  3. Insulin

    Time frame: 12 weeks

    Insulin

  4. HOMA-IR

    Time frame: 12 weeks

    HOMA-IR

Secondary outcomes

  1. Total cholesterol

    Time frame: 12 weeks

    Total cholesterol

  2. HDL-cholesterol

    Time frame: 12 weeks

    HDL-cholesterol

  3. LDL-cholesterol

    Time frame: 12 weeks

    LDL-cholesterol

  4. Triglycerides

    Time frame: 12 weeks

    Triglycerides

  5. Body Mass Index (BMI)

    Time frame: 12 weeks

    Body Mass Index (BMI)

  6. Body Fat Percentage (%BF)

    Time frame: 12 weeks

    Body Fat Percentage (%BF)

  7. Blood pressure

    Time frame: 12 weeks

    Blood pressure

  8. Waist perimeter

    Time frame: 12 weeks

    Waist perimeter

Other outcomes

  1. Mediterranean diet adherence score

    Time frame: 12 weeks

    Mediterranean diet adherence score

Sponsors and collaborators

Lead sponsor

Mónica Marazuela Azpíroz

Other

Collaborators

  • Alba Garcimartín Álvarez
  • Ana María Ramos Levi
  • Belén Ruiz-Rosso
  • Carolina Knott Torcal
  • María Caldas
  • Miguel Antonio Sampedro Núñez
  • Nerea Aguirre Moreno

Registry information

Official study title

A 12 Week, Randomized, Double-blind, Placebo-controlled, Phase II Trial to Evaluate the Efficacy and Safety of the Treatment With BPL-1 in Adult Patients With Type 2 Diabetes Mellitus With Different Course of Disease and Treatment

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Dec 9, 2019
Registry last updated
Jul 8, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.